Wellcome Trust Launches £200 million “Evergreen” Investment Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s charitable foundation The Wellcome Trust has formally launched a £200 million ($325 million) fund that will invest in both early and growth-stage companies, taking a long-term view and focused initially on opportunities in the UK, Europe and on the U.S East Coast.
You may also be interested in...
A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem
The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.
Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease
The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.
Wellcome Trust Launches £200 Million Fund For Diverse Health Care Investments
The U.K.’s largest charitable foundation for biomedical research is the sole investor in a new fund that will target start-ups as well as later-stage growth opportunities across the health care spectrum.